Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Most importantly, don’t leave nutrition and exercise out of the equation. There is a huge difference between a healthy and an unhealthy thin person.

Researchers found after bariatric procedures, patients lost an average of 58 pounds after two years, compared to 12 pounds ...

Researchers found after bariatric procedures, patients lost an average of 58 pounds after two years, compared to 12 pounds ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy. The stock is up ...

New research suggests a link between some weight loss drugs and potentially blinding eye diseases. That risk is especially high for older adults. A recent study found that older adults with diabetes ...

Despite the jump in the number of teens being prescribed Wegovy, it still represents only a small fraction of kids who are living with obesity. Approximately one in 5 children and teens in the U.S.

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

Doctors explain if Berberine, dubbed “Nature’s Ozempic,” can really help with menopause weight loss. Here’s what to know.

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...